Sunshine Biopharma Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Sunshine Biopharma Inc. (SBFM) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$612.52 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$156.69K.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$455.84K.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$565.04K, a 132.20% decline year-over-year.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.22M.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$189.96K, a 104.77% decline from fiscal 2024.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $3.98M.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$1.36M, a 140.61% decline from fiscal 2022.
- Sunshine Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $3.36M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$156.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$612.52K 10-Q · filed 2026-08-13 | -$1.18M derived: sum of 3 quarters · filed 2026-08-13 | $47.22K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$455.84K 10-Q · filed 2026-05-13 | -$1.02M derived: sum of 2 quarters · filed 2026-05-13 | $203.91K derived: sum of 3 quarters · filed 2026-05-13 | -$159.78K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$565.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $659.75K derived: sum of 2 quarters · filed 2026-04-03 | $296.05K derived: sum of 3 quarters · filed 2026-08-13 | -$189.96K 10-K · filed 2026-04-03 |
| 2025-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $861.09K derived: sum of 2 quarters · filed 2026-08-13 | $375.08K 10-Q · filed 2025-11-13 | $2.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$363.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$849.70K 10-Q · filed 2026-08-13 | $904.97K derived: sum of 3 quarters · filed 2026-08-13 | $339.25K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$486.01K 10-Q · filed 2026-05-13 | $1.27M derived: sum of 2 quarters · filed 2026-05-13 | $702.94K derived: sum of 3 quarters · filed 2026-05-13 | $2.20M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $1.19M derived: sum of 2 quarters · filed 2026-04-03 | $2.69M derived: sum of 3 quarters · filed 2026-04-03 | $3.98M 10-K · filed 2026-04-03 |
| 2024-09-30 | -$565.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $935.70K derived: sum of 2 quarters · filed 2025-11-13 | $2.23M 10-Q · filed 2025-11-13 | $1.45M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.79M 10-Q · filed 2025-08-12 | $2.02M derived: sum of 3 quarters · filed 2025-08-12 | $2.53M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.29M 10-Q · filed 2025-05-15 | $517.21K derived: sum of 2 quarters · filed 2025-05-15 | $1.03M derived: sum of 3 quarters · filed 2025-05-15 | $2.90K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$776.16K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | -$260.63K derived: sum of 2 quarters · filed 2025-04-01 | -$1.29M derived: sum of 3 quarters · filed 2025-04-01 | -$1.36M 10-K · filed 2025-04-01 |
| 2023-09-30 | $515.53K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-05 | -$514.31K derived: sum of 2 quarters · filed 2024-11-05 | -$587.97K 10-Q · filed 2024-11-05 | $2.33M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$1.03M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2024-08-20 | -$1.10M 10-Q/A · filed 2024-08-20 | $1.82M derived: sum of 3 quarters · filed 2024-08-20 | $2.19M derived: sum of 4 quarters · filed 2024-08-20 |
| 2023-03-31 | -$73.66K 10-Q · filed 2024-05-20 | $2.85M derived: sum of 2 quarters · filed 2024-05-20 | $3.22M derived: sum of 3 quarters · filed 2024-05-20 | $3.23M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.30M derived: sum of 2 quarters · filed 2024-03-28 | $3.31M derived: sum of 3 quarters · filed 2024-03-28 | $3.36M 10-K · filed 2024-03-28 |
| 2022-09-30 | $375.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $384.98K derived: sum of 2 quarters · filed 2023-11-13 | $437.27K 10-Q · filed 2023-11-13 | $432.89K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $9.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $61.74K 10-Q · filed 2023-08-10 | $57.36K derived: sum of 3 quarters · filed 2023-08-10 | $8.06K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $52.29K 10-Q · filed 2023-05-10 | $47.91K derived: sum of 2 quarters · filed 2023-05-10 | -$1.39K derived: sum of 3 quarters · filed 2023-05-10 | -$47.43K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$4.38K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-04 | -$53.68K derived: sum of 2 quarters · filed 2023-04-04 | -$99.72K derived: sum of 3 quarters · filed 2023-04-04 | -$18.16K 10-K · filed 2023-04-04 |
| 2021-09-30 | -$49.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$95.35K derived: sum of 2 quarters · filed 2022-11-07 | -$13.78K 10-Q · filed 2022-11-07 | -$8.76K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$46.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $35.52K 10-Q · filed 2022-08-03 | $40.54K derived: sum of 3 quarters · filed 2022-08-03 | $4.11K derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $81.57K 10-Q · filed 2022-05-06 | $86.58K derived: sum of 2 quarters · filed 2022-05-06 | $50.15K derived: sum of 3 quarters · filed 2022-05-06 | $45.40K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $5.02K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$31.42K derived: sum of 2 quarters · filed 2022-03-21 | -$36.17K derived: sum of 3 quarters · filed 2022-03-21 | -$35.01K 10-K · filed 2022-03-21 |
| 2020-09-30 | -$36.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$41.19K derived: sum of 2 quarters · filed 2021-11-09 | -$40.03K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$4.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$3.59K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $1.16K 10-Q · filed 2021-05-11 | |||
| 2019-09-30 | -$21.04K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-12 | $937.00 derived: sum of 2 quarters · filed 2020-11-12 | -$52.49K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $21.98K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | -$31.45K 10-Q/A · filed 2020-08-31 | ||
| 2019-03-31 | -$53.43K 10-Q · filed 2020-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |